[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-carcinoma-stage-i\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-carcinoma-stage-i":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100488976","patient-derived-tumor-like-cell-clusters-predict-progesterone-sensitivity-in-patients-with-early-endometrial-cancer-100488976",false,"NCT05647109","Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer","Department of Obstetrics & Gynecology ，Peking University People's Hospital","Inclusion Criteria:\n\n* Have a confirmed pathological diagnosis based upon hysteroscopy: atypical endometrial hyperplasia or histologically prove well-differentiated EEC G1 without myometrial invasion\n* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound\n* Have a desire for remaining reproductive function or uterus\n* Good compliance with adjunctive treatment and follow-up\n\nExclusion Criteria:\n\n* Acute liver disease or liver tumor (benign or malignant) or renal dysfunction\n* Pregnancy or potential pregnancy\n* Confirmed diagnosis of any cancer in reproductive system\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* Hypersensitivity or contradiction for using MPA or MA\n* With other factors of reproductive dysfunction;\n* Strong request for uterine removal or other conservative treatment","FEMALE","17 Years","45 Years",{"count":20,"type":21},244,"ESTIMATED","1 Year","OBSERVATIONAL","To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation",[26,27],"Endometrial Carcinoma Stage I","Atypical Endometrial Hyperplasia",[29,30,31],"Progesterone","Patient-derived tumor-like cell clusters","Endometrial Carcinoma","RECRUITING","2025-05-02",{"date":35,"type":36},"2025-05-04","ACTUAL",{"date":38,"type":36},"2021-09-01",{"date":40,"type":21},"2025-10-31",{"name":42,"class":43},"Peking University People's Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":44},"100491181","phase-2-medroxyprogesterone-acetate-plus-atorvastatin-in-young-women-with-early-endometrial-carcinoma-and-atypical-endometrial-hyperplasia-100491181","NCT05675787","Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia","Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma","Inclusion Criteria:\n\n* Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove AEH or well-differentiated EEC G1 without myometrial invasion: 1. Untreated patients; 2. Patients with persistent lesions after one course (12 weeks) of progesterone therapy; 3. Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy;\n* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound\n* Have a desire for remaining reproductive function or uterus\n* Good compliance with adjunctive treatment and follow-up\n\nExclusion Criteria:\n\n* Hypersensitivity or contradiction for using MPA or atorvastatin\n* Pregnancy or potential pregnancy\n* Confirmed diagnosis of any cancer in reproductive system\n* Already diagnosed with hyperlipidemia and using lipid-lowering drugs\n* Acute liver disease or liver tumor (benign or malignant) or renal dysfunction\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* With other factors of reproductive dysfunction;\n* Strong request for uterine removal or other conservative treatment\n* Smoker (\\>15 cigarettes a day)\n* Drinker (\\>20 grams a day)",{"count":53,"type":21},82,"INTERVENTIONAL",[56],"PHASE2","To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.",[27,26],[31,27],"2024-07-09",{"date":62,"type":36},"2024-07-11",{"date":64,"type":36},"2023-01-06",{"date":40,"type":21},{"name":42,"class":43}]